Cefoperazone

Cefoperazone

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Cefoperazone
Category Antibiotics
Catalog number BBF-00728
CAS 62893-19-0
Molecular Weight 645.67
Molecular Formula C25H27N9O8S2
Purity ≥98%

Online Inquiry

Description

It is produced by the strain of Semisynthetic third generation cephalosporin for injection. Cefoperazone with the third generation of cephalosporin connectivity, and has good antibacterial effect to pseudomonas aeruginosa (MIC90 is 8 ㎍/mL). It is also used in the treatment of Pseudomonas infections. It has been used to treat respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia.

Specification

Related CAS 62893-20-3 (sodium)
Synonyms Cefobid; Cefoperazono; Cefoperazonum; Medocef; Cefob; WAY-362450; FXR-450; WAY 362450; FXR 450; WAY362450; FXR450; T1551; T-1551; T 1551; C06883; C-06883; C 06883; D07645; D-07645; D 07645; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-
Storage −20 °C
IUPAC Name (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Canonical SMILES CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
InChI InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1
InChI Key GCFBRXLSHGKWDP-XCGNWRKASA-N

Properties

Appearance White Crystal Powder
Application Anti-Bacterial Agents
Melting Point > 176 °C (dec.)
Density 1.77±0.1 g/cm3 (Predicted)
Solubility Slightly soluble in DMSO, Methanol (Heated, Sonicated)

Reference Reading

1.The Distribution and Resistance of Pathogens Among Solid Organ Transplant Recipients with Pseudomonas aeruginosa Infections.
Wan Q1, Luo A2, Zhong Z3, Ye Q4. Med Sci Monit. 2016 Apr 5;22:1124-1130.
BACKGROUND Pseudomonas aeruginosa infection remains a life-threatening complication after solid organ transplantation (SOT). We aimed to investigate the distribution and drug susceptibility of pathogens, and clinical characteristics of SOT recipients with Pseudomonas aeruginosa infections. MATERIAL AND METHODS A total of 55 SOT recipients who developed 61 episodes of Pseudomonas aeruginosa infections between January 1, 2003 and July 31, 2015 were retrospectively analyzed. The distribution and the drug susceptibility of Pseudomonas aeruginosa were reviewed. RESULTS The most common site from which 61 Pseudomonas aeruginosa rods were isolated were the lungs (57.4%, n=37), followed by the blood (27.9%, n=17). There were 35, 18, and 9 recipients accompanied with a serum creatinine level of >1.5 mg/dL, lymphocyte count of <300/mm3, and a serum albumin level of <30 g/L, respectively. Seven patients each presented with white blood cell count of >15 000/mm3 and platelet count of <50 000/mm3.
2.Analysis of drug resistance in 1,861 strains of Acinetobacter baumannii.
Jin H1, Qiu F2, Ji HJ1, Lu Q1. Biomed Rep. 2016 Apr;4(4):463-466. Epub 2016 Feb 15.
Acinetobacter baumannii is an emerging human pathogen that causes hospital-acquired infections. The trend in increased antimicrobial resistance limits the choice of effective antimicrobial agents. The present study reports the resistance to Acinetobacter baumannii and analyzes the associations between antibiotic use and resistance rates at a general hospital between 2010 and 2014. A total of 1,861 isolates were obtained from clinical cultures, accounting for 10.33% of all detected bacteria (1,861/18,016). The strains were mainly from respiratory samples (1,628 isolates, 87.5%) and the intensive care unit (696 isolates, 37.4%). The resistance rates of Acinetobacter baumannii to the majority of antibiotics were >50%, particularly the resistance rate to cefoperazone/sulbactam increased from 47.37 in 2011 to 89.25% in 2014. However, the rates of imipenem and cilastatin sodium decreased from 81.03 to 69.44% due to the antibiotic policy. There were Pearson significant associations between the use of three antibiotics and resistance in Acinetobacter baumannii to this drug, piperacillin/tazobactam (r=0.
3.Molecular characterization of carbapenemase genes in Acinetobacter baumannii in China.
Fang F1, Wang S2, Dang YX3, Wang X3, Yu GQ3. Genet Mol Res. 2016 Mar 31;15(1). doi: 10.4238/gmr.15017432.
Acinetobacter baumannii is an aerobic non-motile Gram-negative coccobacillus, and it is one of the most important nosocomial pathogens worldwide. The aim of this study was to determine the molecular epidemiology of the outbreak strains. Between March 2011 and March 2014, a total of 205 strains of A. baumannii were isolated from patients at the Nanyang City Center Hospital. The blaOXA-23, blaOXA-24, blaOXA-51, and blaOXA-58 genes were amplified by multiplex polymerase chain reaction. We found that 68 (33.17%) strains were positive for the blaOXA-23 gene, and 88.24% of these 68 showed resistance to carbapenems, while 11.76% were sensitive to carbapenems. The blaOXA-51 gene was found in 132 (64.39%) strains, and 17.42% of these were resistant to carbapenems while 82.58% were sensitive to carbapenems. Moreover, 5 (2.44%) strains were positive for blaOXA-58, of which 80% were resistant to carbapenems and 20% were sensitive to carbapenems. We found that A.
4.The resistance and transmission mechanism of Acinetobacter baumannii isolates in a tertiary care hospital, China.
Sun F1, Ou Q1, Wang Q2, Feng W1, Qiu X1, Chen J1, Liu Y1, Xia P1. J Chemother. 2016 Mar 30:1-6. [Epub ahead of print]
The aim of this study was to analyse the resistance and epidemiological data of 117 Acinetobacter baumannii isolates from Southwest Hospital, Chongqing, China. Except for polymyxin B, tigecycline, minocycline, cefoperazone/sulbactam, amikacin and levofloxacin, the resistance rates of other antimicrobial agents were above 90%. All the clinical isolates had the blaOXA-51 gene and 114 isolates had the blaOXA-23 gene. Forty-nine isolates were found to contain the blaIMP-4 gene. PFGE data showed that 117 isolates were divided into 25 groups. Sixty-three (53.85%) were found to carry the class 1 integron, and the sequence analysis of the class 1 integron internal variable regions - five types, one of which had the blaIMP-4 gene. For the blaIMP-4 positive strain without class 1 integron, we found the flanking sequence had the TnpA gene. The result suggested that the resistance gene was widely distributed in our hospital; moreover, the modes of presence and transmission are different and complicated.

Recommended Products

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket